APPROVED: FDA OK's Sunovion epilepsy drug Aptiom
This article was originally published in Scrip
Executive Summary
Sunovion Pharmaceuticals gained the US FDA's blessing to market Aptiom (eslicarbazepine acetate) as an add-on medication to treat partial-onset seizures associated with epilepsy, a neurological disorder caused by abnormal or excessive activity in the brain's nerve cells.